NCT01756898 - Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis | Biotech Hunter

Enrollment

370

Participants

Timeline

Start Date

November 28, 2012

Primary Completion Date

January 14, 2014

Study Completion Date

January 14, 2014

Conditions

Atopic Dermatitis

Interventions

DRUG

5 mg ASB17061

Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.

DRUG

Placebo

Oral administration of placebo taken once daily for 28 consecutive days.

DRUG

10 mg ASB17061

Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.

DRUG

20 mg ASB17061

Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.

Trial Locations (40)

11790

Stony Brook

23233

Henrico

23507

Norfolk

27612

Raleigh

31405

Savannah

32086

Saint Augustine

33027

Miramar

33144

Miami

33175

Miami

33609

South Tampa

Tampa

33613

Tampa

35233

Birmingham

43560

Sylvania

48038

Clinton Township

48059

Fort Gratiot

48706

Bay City

66215

Overland Park

70526

Crowley

72758

Rogers

76011

Arlington

77598

Webster

77845

College Station

78229

San Antonio

78660

Pflugerville

80220

Denver

83704

Boise

84020

Draper

84088

West Jordan

85018

Phoenix

91436

Encino

92122

San Diego

92592

Temecula

94538

Fremont

97035

Lake Oswego

97239

Portland

08009

Berlin

07044

Verona

02919

Johnston

99204-4880

Spokane